Zoetis Inc. ZTS

What this company does

Zoetis Inc. discovers, develops, manufactures and commercializes medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health products, commercializing them across eight core species -- dogs, cats and horses, and cattle, swine, poultry, fish and sheep -- within seven major product categories, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical products and animal health diagnostics. As of December 31, 2025, the company employed approximately 14,500 people worldwide, including approximately 6,800 in the United States and approximately 7,700 in other jurisdictions. Sales to Zoetis's largest customer, a U.S. veterinary distributor, accounted for approximately 16% of its total revenue in 2025. Zoetis organizes and operates its business in two segments: United States, which generated $5,097 million, or 54% of total revenue, in 2025; and International, which generated $4,254 million, or 45% of total revenue, in the same year. Its global manufacturing and supply chain relies on a network of more than 90 contract manufacturing organizations, both centrally managed and locally managed, as of December 31, 2025. The company was incorporated in Delaware in July 2012, prior to which it operated as a business unit of Pfizer Inc.

Written from the business description in Zoetis Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 12 February 2026. Every sentence was checked against that document before publication.